Country: United States
Language: English
Source: NLM (National Library of Medicine)
ERYTHROMYCIN (UNII: 63937KV33D) (ERYTHROMYCIN - UNII:63937KV33D)
H.J. Harkins Company, Inc.
ERYTHROMYCIN
ERYTHROMYCIN 5 mg in 1 g
OPHTHALMIC
PRESCRIPTION DRUG
For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.
Erythromycin Ophthalmic Ointment USP, 0.5% is available in the following sizes: 1/8 oz. (3.5 g) tamper-resistant tube – 09234 DO NOT USE IF CAP AND NECKRING ARE NOT INTACT. 1 g tin container (in cartons of 50) DO NOT USE IF BOTTOM RIDGE OF TUBE CAP IS EXPOSED. Store between 15°-30°C (59°-86°F). KEEP OUT OF REACH OF CHILDREN. Revised February 2007 Bausch & Lomb Incorporated Tampa, FL 33637 ©Bausch & Lomb Incorporated H.J. Harkins Company, Inc. Nipomo, CA 93444 9043401 (Folded) 9043501 (Flat)
Abbreviated New Drug Application
ERYTHROMYCIN - ERYTHROMYCIN OINTMENT H.J. HARKINS COMPANY, INC. ---------- ERYTHROMYCIN OPHTHALMIC OINTMENT USP, 0.5% (STERILE) RX ONLY DESCRIPTION: Erythromycin Ophthalmic Ointment USP belongs to the macrolide group of antibiotics. The sterile ophthalmic ointment flows freely over the conjunctiva. Erythromycin base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin is an antibiotic produced from a strain of _Streptomyces erythraeus. _It is basic and readily forms a salt when combined with an acid. It has the following structural formula: C H NO Mol. Wt. 733.94 Chemical Name: (3R , 4S , 5S , 6R , 7R , 9R , 11R , 12R , 13S , 14R )-4-[(2,6-Dideoxy-3-_C_-methyl- 3-_0_-methyl-α-L-_ribo_-hexopyranosyl)oxy]-14-ethyl-7, 12, 13-trihydroxy-3, 5, 7, 9, 11, 13-hexamethyl-6- [[3,4,6-trideoxy-3-(dimethylamino)-_β_-D-_xylo_-hexopyranosyl]oxy]oxacyclotetradecane-2, 10-dione Each Gram Contains: ACTIVE: Erythromycin, USP 5 mg (0.5%); INACTIVES: White Petrolatum, Mineral Oil. CLINICAL PHARMACOLOGY: MICROBIOLOGY Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms _in vitro _and in clinical infections: _Streptococcus pyogenes_ (group A β-hemolytic), Alpha-hemolytic streptococci (viridans group); _Staphylococcus aureus,_ including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin); _Streptococcus pneumoniae; Mycoplasma pneumoniae _(Eaton Agent, PPLO); _Haemophilus_ _influenzae _(not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved); _Treponema pallidum; Corynebacterium diphtheriae; Neisseria gonorrhoeae; Chlamydia_ _trachomatis._ 37 67 13 • • • • • • • • • • INDICATIONS AND USAGE: For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For Read the complete document